Computational Drug Discovery and Repurposing for the Treatment of COVID-19: A Systematic Review

TL;DR: In this article, a systematic review of published studies concerning pregnant women with confirmed COVID-19 and their neonates was carried out in multiple databases, including PubMed, Web of Science, Google Scholar, Scopus, and WHO COVID19 database.

TL;DR: In this article , a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease were systematically reviewed and the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, and the review can provide important insights for follow-up research.

TL;DR: In this paper, the authors proposed to use drug repurposing screens to identify effective synergistic drug candidates for emerging and re-emerging viruses, such as influenza, severe acute respiratory syndrome-coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS)-CoV, Ebola, Zika, and SARS-CORONAVirus 2 (CoV-2).

TL;DR: The COVID-19 pandemic has emerged since December 2019 and has affected the global economy in many ways as discussed by the authors, including increased health expenditures and reduced labor force, and caused trouble for manufacturers who have to fire some of their employees or delay their economic activities to prevent more loss.

TL;DR: A reporting guideline is described, the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015), which consists of a 17-item checklist intended to facilitate the preparation and reporting of a robust protocol for the systematic review.

TL;DR: The PRISMA-P checklist as mentioned in this paper provides 17 items considered to be essential and minimum components of a systematic review or meta-analysis protocol, as well as a model example from an existing published protocol.